Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart
The Journal of Cardiovascular Aging · 03.06.2024 · 4 (2)
DOI: 10.20517/jca.2024.06 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Cardiovascular Aging, online erschienen am 03.06.2024. Verfasst von Peiyong Zhai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Cellular senescence in cardiomyocytes, characterized by cell cycle arrest, resistance to apoptosis, and the senescence-associated secretory phenotype, occurs during aging and in response to various stresses, such as hypoxia/reoxygenation, ischemia/reperfusion, myocardial infarction (MI), pressure overload, doxorubicin treatment, angiotensin II, diabetes, and thoracic irradiation. Senescence in the heart has both beneficial and detrimental effects. Premature senescence of myofibroblasts has salutary effects during MI and pressure overload. On the other hand, persistent activation of senescence in cardiomyocytes precipitates cardiac dysfunction and adverse remodeling through paracrine mechanisms during MI, myocardial ischemia/reperfusion, aging, and doxorubicin-induced cardiomyopathy. Given the adverse roles of senescence in many conditions, specific removal of senescent cells, i.e., senolysis, is of great interest. Senolysis can be achieved using senolytic drugs (such as Navitoclax, Dasatinib, and Quercetin), pharmacogenetic approaches (including INK-ATTAC and AP20187, p16-3MR and Ganciclovir, p16 ablation, and p16-LOX-ATTAC and Cre), and immunogenetic interventions (CAR T cells or senolytic vaccination). In order to enhance the specificity and decrease the off-target effects of senolytic approaches, investigation into the mechanisms through which cardiomyocytes develop and/or maintain the senescent state is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Zhai, P., & Sadoshima, J. (2024). Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart. The Journal of Cardiovascular Aging, 4(2). https://doi.org/10.20517/jca.2024.06
Vancouver
Zhai P, Sadoshima J. Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart. The Journal of Cardiovascular Aging. 2024;4(2). doi:10.20517/jca.2024.06
BibTeX
@article{Zhai2024,
author = {Zhai, Peiyong and Sadoshima, Junichi},
title = {Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart},
journal = {The Journal of Cardiovascular Aging},
year = {2024},
volume = {4},
number = {2},
doi = {10.20517/jca.2024.06}
}
EUVIMED